Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 3

4(40.0%)

Phase 1

4(40.0%)

Phase 2

2(20.0%)

10Total

Phase 3(4)

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07299019Phase 3Recruiting

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Role: lead

NCT05662241Phase 3Active Not Recruiting

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

Role: lead

NCT07067463Phase 3Recruiting

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Role: lead

NCT06564311Phase 2Active Not Recruiting

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Role: lead

NCT06559163Phase 2Recruiting

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

Role: lead

NCT05786573Phase 3Active Not Recruiting

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

Role: lead

NCT05794516Phase 1Completed

A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants

Role: lead

NCT05776121Phase 1Completed

Study of ZB001 in Chinese Patients With Thyroid Eye Disease

Role: lead

NCT05638854Phase 1Recruiting

A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis

Role: lead

NCT05542303Phase 1Completed

A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects

Role: lead

All 10 trials loaded